Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yara Mouhamed, Andrey Vishnyakov, Bessi Qorri, Manpreet Sambi, SM Signy Frank, Catherine Nowierski, Anmol Lamba, Umrao Bhatti & Myron R Szewczuk. (2018) Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. Drug, Healthcare and Patient Safety 10, pages 45-66.
Read now
Read now
Adrien Gras & Julie Broughton. (2016) A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis. Expert Review of Pharmacoeconomics & Outcomes Research 16:6, pages 771-779.
Read now
Read now
Carlo Pozzilli. (2013) Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Review of Neurotherapeutics 13:sup2, pages 49-54.
Read now
Read now
Ralf Gold. (2013) Multiple sclerosis spasticity management – key publications. Expert Review of Neurotherapeutics 13:sup2, pages 47-48.
Read now
Read now
Articles from other publishers (18)
Daniel Erku, Shakti Shrestha & Paul Scuffham. (2021) Cost-Effectiveness of Medicinal Cannabis for Management of Refractory Symptoms Associated With Chronic Conditions: A Systematic Review of Economic Evaluations. Value in Health 24:10, pages 1520-1530.
Crossref
Crossref
Paolo De Blasiis, Maria Francesca Siani, Allegra Fullin, Mario Sansone, Mariarosa Anna Beatrice Melone, Simone Sampaolo, Elisabetta Signoriello & Giacomo Lus. (2021) Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity.. Multiple Sclerosis and Related Disorders 51, pages 102805.
Crossref
Crossref
Christopher Vannabouathong, Meng Zhu, Yaping Chang & Mohit Bhandari. (2021) Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders 14, pages 117954412110024.
Crossref
Crossref
RR Zafar, AK Schlag & DJ Nutt. (2020) Ending the pain of children with severe epilepsy? An audit of the impact of medical cannabis in 10 patients. Drug Science, Policy and Law 6, pages 205032452097448.
Crossref
Crossref
P. De Blasiis, M.F. Siani, G. Iolascon, M. Sansone, E. Signoriello, S. Sampaolo & G. Lus. (2019) Clinical and 3D instrumental assessment of the short-term effect of Sativex on patients with multiple sclerosis. Gait & Posture 74, pages 12.
Crossref
Crossref
Shaun H. Medina, Vidushan Nadarajah, Julio J. Jauregui, Michael P. Smuda, Michael Foster, Sean J. Meredith, Jonathan D. Packer & R. Frank HennIIIIII. (2018) Orthopaedic surgery patients who use recreational marijuana have less pre-operative pain. International Orthopaedics 43:2, pages 283-292.
Crossref
Crossref
Giuseppe Lanza, Raffaele Ferri, Rita Bella & Luigi Ferini-Strambi. (2016) The impact of drugs for multiple sclerosis on sleep. Multiple Sclerosis Journal 23:1, pages 5-13.
Crossref
Crossref
Uwe K. Zettl, Paulus Rommer, Petra Hipp & Robert Patejdl. (2015) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Therapeutic Advances in Neurological Disorders 9:1, pages 9-30.
Crossref
Crossref
G. Coghe, M. Pau, F. Corona, J. Frau, L. Lorefice, G. Fenu, G. Spinicci, E. Mamusa, L. Musu, S. Massole, R. Massa, M. G. Marrosu & E. Cocco. (2015) Walking improvements with nabiximols in patients with multiple sclerosis. Journal of Neurology 262:11, pages 2472-2477.
Crossref
Crossref
William G. Notcutt. (2015) Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis. Neurotherapeutics 12:4, pages 769-777.
Crossref
Crossref
C. Lebrun & P. Vermersch. (2015) Une avancée pour la prise en charge de la spasticité dans la sclérose en plaques. Revue Neurologique 171:4, pages 327-328.
Crossref
Crossref
Donald E. Greydanus, Gabriel Kaplan, Louis E. BaxterSrSr, Dilip R. Patel & Cynthia L. Feucht. (2015) Cannabis: The never-ending, nefarious nepenthe of the 21st century: What should the clinician know?. Disease-a-Month 61:4, pages 118-175.
Crossref
Crossref
Franziska Gläser, Manuel C. Bröhmer, Thomas Hurrle, Martin Nieger & Stefan Bräse. (2015)
The Diels-Alder Approach to Δ
9
-Tetrahydrocannabinol Derivatives
. European Journal of Organic Chemistry 2015:7, pages 1516-1524.
Crossref
Crossref
Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez-Ruiz, Jacqueline French, Charlotte Hill, Russell Katz, Vincenzo Di Marzo, Didier Jutras-Aswad, William George Notcutt, Jose Martinez-Orgado, Philip J. Robson, Brian G. Rohrback, Elizabeth Thiele, Benjamin Whalley & Daniel Friedman. (2014) Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55:6, pages 791-802.
Crossref
Crossref
Martin Kaczocha, Mario J. Rebecchi, Brian P. Ralph, Yu-Han Gary Teng, William T. Berger, William Galbavy, Matthew W. Elmes, Sherrye T. Glaser, Liqun Wang, Robert C. Rizzo, Dale G. Deutsch & Iwao Ojima. (2014) Inhibition of Fatty Acid Binding Proteins Elevates Brain Anandamide Levels and Produces Analgesia. PLoS ONE 9:4, pages e94200.
Crossref
Crossref
Peter Flachenecker, Thomas Henze & Uwe K. Zettl. (2014) Long-Term Effectiveness and Safety of Nabiximols (Tetrahydrocannabinol/Cannabidiol Oromucosal Spray) in Clinical Practice. European Neurology 72:1-2, pages 95-102.
Crossref
Crossref
Jürgen Koehler. (2014) Who Benefits Most from THC:CBD Spray? Learning from Clinical Experience. European Neurology 71:Suppl. 1, pages 10-15.
Crossref
Crossref
Carlo Pozzilli. (2014) Overview of MS Spasticity. European Neurology 71:Suppl. 1, pages 1-3.
Crossref
Crossref